MENU
+Compare
ARKG
ETF ticker: BATS
AS OF
Apr 24, 04:59 PM (EDT)
Price
$22.48
Change
+$0.71 (+3.26%)
Net Assets
920.84M

ARKG stock forecast, quote, news & analysis

The investment seeks long-term growth of capital... Show more

Category: #Health
ARKG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for ARKG with price predictions
Apr 23, 2025

ARKG's Stochastic Oscillator is staying in overbought zone for 6 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 50-day moving average for ARKG moved below the 200-day moving average on April 03, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ARKG entered a downward trend on April 07, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARKG's RSI Indicator exited the oversold zone, of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 17, 2025. You may want to consider a long position or call options on ARKG as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ARKG just turned positive on April 11, 2025. Looking at past instances where ARKG's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .

ARKG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Market Cap

The average market capitalization across the ARK Genomic Revolution ETF ETF is 70.95B. The market cap for tickers in the group ranges from 58.24M to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is RPTX at 58.24M.

High and low price notable news

The average weekly price growth across all stocks in the ARK Genomic Revolution ETF ETF was 41%. For the same ETF, the average monthly price growth was 38%, and the average quarterly price growth was 131%. PRME experienced the highest price growth at 42%, while PACB experienced the biggest fall at -3%.

Volume

The average weekly volume growth across all stocks in the ARK Genomic Revolution ETF ETF was -26%. For the same stocks of the ETF, the average monthly volume growth was 10% and the average quarterly volume growth was 45%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 82
Price Growth Rating: 64
SMR Rating: 86
Profit Risk Rating: 90
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
ARKG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
ARK ETF Trust155 West 19th Street, 5th FloorNew York
Phone
212-426-7040
Web
www.ark-funds.com